Deubiquitylating enzymes and drug discovery: emerging opportunities

Nature Reviews Drug Discovery 17, 57 (2018). doi:10.1038/nrd.2017.152 Authors: Jeanine A. Harrigan, Xavier Jacq, Niall M. Martin & Stephen P. Jackson More than a decade after a Nobel Prize was awarded for the discovery of the ubiquitin–proteasome system and clinical approval of proteasome and ubiquitin E3 ligase inhibitors, first-generation deubiquitylating enzyme (DUB) inhibitors are now approaching clinical trials. However, although our knowledge of the physiological and
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Review Source Type: research